Log in

Relevant bibliographies by topics / Daclatasvir Dihydrochloride / Journal articles

To see the other types of publications on this topic, follow the link: Daclatasvir Dihydrochloride.

Journal articles on the topic 'Daclatasvir Dihydrochloride'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 31 journal articles for your research on the topic 'Daclatasvir Dihydrochloride.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.036.10.1703570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Reviriego, C. "Daclatasvir dihydrochloride." Drugs of the Future 36, no. 10 (2011): 735. http://dx.doi.org/10.1358/dof.2011.36.10.1703570.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ravindra S Morey, Ganesh G Tapadiya, and Manisha V Doud. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. http://dx.doi.org/10.30574/wjarr.2024.23.2.2569.

Full text

Abstract:

A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Dihydrochlorid

APA, Harvard, Vancouver, ISO, and other styles

4

Ravindra, S. Morey, G. Tapadiya Ganesh, and V. Doud Manisha. "Development and validation of stability indicating HPTLC method for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form." World Journal of Advanced Research and Reviews 23, no. 2 (2024): 2470–78. https://doi.org/10.5281/zenodo.14891592.

Full text

Abstract:

A high-performance thin-layer chromatographic method was developed and validated for estimation of Daclatasvir Dihydrochloride in pharmaceutical dosage form. The proposed method was applied successfully to the pharmaceutical analysis of the recently approved dosage form of Daclatasvir Dihydrochloride which is available in market as a brand name of ‘NALDAC 60’ tablets. The drugs were satisfactorily show peak with RF 0.38 for Daclatasvir Dihydrochloride. Method was validated according to the ICH guidelines. The calibration plot was linear between 50-300 ng per band for Daclatasvir Di

APA, Harvard, Vancouver, ISO, and other styles

5

Hodge, Ryan L., James A. Kaduk, Amy M. Gindhart, and Thomas N. Blanton. "Powder X-ray diffraction of daclatasvir dihydrochloride Form N-2 (Daklinza®), C40H52N8O6Cl2." Powder Diffraction 36, no. 3 (2021): 208–11. http://dx.doi.org/10.1017/s0885715621000397.

Full text

Abstract:

The crystal structure of daclatasvir dihydrochloride Form N-2 (Daklinza®) has been refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Daclatasvir dihydrochloride, Form N-2, crystallizes in space group P1 (#1) with a = 7.54808 (15), b = 9.5566 (5), c = 16.2641 (11) Å, α = 74.0642 (24), β = 84.0026 (13), γ = 70.6322 (5)°, V = 1064.150(11) Å3, and Z = 1. The hydrogen bonds were identified and quantified. Strong N–H⋯Cl hydrogen bonds link the cations and anions in chains along the a-axis. The powder pattern has been submitted to ICDD®

APA, Harvard, Vancouver, ISO, and other styles

6

Sarfraz, Sadaf, Muhammad Saeed, Mohsin Javed, et al. "Validation of a Cost-Effective RP-HPLC Method for Quantitative Investigation of Daclatasvir Dihydrochloride in Pharmaceutical Formulations." Journal of Chemistry 2023 (August 3, 2023): 1–9. http://dx.doi.org/10.1155/2023/4908091.

Full text

Abstract:

A well-known direct-acting antiviral (DAA) drug called daclatasvir may be used to treat chronic hepatitis C virus (HCV) infection. Herein, we reported a selective, precise, and a cost-effective analytical method for the measurement of an active pharmaceutical ingredient (API) of daclatasvir dihydrochloride in drug substances as well as drug products via the reversed-phase RP-HPLC technique. To obtain greater separation, the majority of the chromatographic conditions were improved. Best separation findings were achieved under chromatographic conditions with an HPLC column of USP L1 (150 × 4.6 m

APA, Harvard, Vancouver, ISO, and other styles

7

Rathod, Sapna M., and Paresh U. Patel. "CHEMOMETRICS ASSISTED SPECTROSCOPIC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF SOFOSBUVIR AND DACLATASVIR DIHYDROCHLORIDE IN TABLET FORMULATION." INDIAN DRUGS 57, no. 03 (2020): 37–46. http://dx.doi.org/10.53879/id.57.03.12273.

Full text

Abstract:

Four chemometric methods, namely Classical Least Square (CLS), Inverse Least Square (ILS), Partial Least Square (PLS) and Principal Component Regression (PCR), were developed for the simultaneous estimation of sofosbuvir and daclatasvir dihydrochloride in tablet formulation. Full factorial design was used to construct calibration set as well as validation set. Twenty five mixed solutions were prepared for calibration set and sixteen mixed solution of drugs were prepared for validation set. The absorbance of all prepared solutions was measured in the range of 230 nm to 335 nm at 16 wavelength p

APA, Harvard, Vancouver, ISO, and other styles

8

Hussar, Daniel A., and Joellen Friedman. "Ceftazidime pentahydrate/avibactam sodium, Isavuconazonium sulfate, and Daclatasvir dihydrochloride." Journal of the American Pharmacists Association 56, no. 1 (2016): 100–103. http://dx.doi.org/10.1016/j.japh.2015.12.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

B, Jeevana Jyothi, and Padmaja G. "UV SPECTROPHOTOMETRIC METHOD FOR ESTIMATION OF NEW DRUG, DACLATASVIR DIHYDROCHLORIDE." International Research Journal of Pharmacy 7, no. 9 (2016): 1–3. http://dx.doi.org/10.7897/2230-8407.079104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Badawy, Sayed S., Yomna M. Ahmed, and M. A. Sultan. "Voltammetric determination of daclatasvir dihydrochloride at bimetallic Ag/Co nanoparticles modified carbon paste electrode." Microchemical Journal 191 (August 2023): 108799. http://dx.doi.org/10.1016/j.microc.2023.108799.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Nimje, Hemlata M., and Meenakshi N. Deodhar. "STABILITY-INDICATING HPTLC METHOD FOR DETERMINATION OF DACLATASVIR IN PHARMACEUTICAL DOSAGE FORM." INDIAN DRUGS 58, no. 4 (2021): 56–62. http://dx.doi.org/10.53879/id.58.04.11662.

Full text

Abstract:

A simple, specific, precise, and accurate stability-indicating assay method using high performance thinlayer chromatography (HPTLC) is described for estimation of daclatasvir dihydrochloride (DCV) in bulk drug and in the tablet dosage form. The separations were achieved on prepared TLC plates precoated with silica gel 60 F254. The mobile phase developed and optimized for bringing out the separation involves toluene: methanol in the ratio of (6:4 V/V). The densitometric scanning wavelength selected was 312.0 nm. The compact bands of DCV were obtained at RF value of 0.702±0.032. The method devel

APA, Harvard, Vancouver, ISO, and other styles

12

Hendawy, Hassan A. M., Ghada M. G. Eldin, and Amany M. Fekry. "A Zirconium Oxide Nanoparticle Modified Screen‐printed Electrode for Anodic Stripping Determination of Daclatasvir Dihydrochloride." Electroanalysis 31, no. 5 (2019): 858–66. http://dx.doi.org/10.1002/elan.201800841.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Abdel-Lateef, Mohamed A., Mahmoud A. Omar, Ramadan Ali, and Sayed M. Derayea. "Xanthene based spectroscopic probe for the analysis of HCV antiviral, daclatasvir dihydrochloride, through feasible complexation reaction." Microchemical Journal 145 (March 2019): 672–75. http://dx.doi.org/10.1016/j.microc.2018.11.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hassib, Sonia T., Elham A. Taha, Ehab F. Elkady, and Ghada H. Barakat. "Reversed-Phase Liquid Chromatographic Method for Determination of Daclatasvir Dihydrochloride and Study of Its Degradation Behavior." Chromatographia 80, no. 7 (2017): 1101–7. http://dx.doi.org/10.1007/s10337-017-3321-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Abdalla, Shalaby, El-Maamly Magda, M. Abdel-Gawad Fatma, M. Azab Shereen, and S. Eldin Amira. "Spectrophotometric Determination of Daclatasvir Dihydrochloride by Ion-Pair Reaction with Bromophenol Blue, Bromothymol Blue and Bromocresol Green." Chemistry Research Journal 2, no. 6 (2017): 163–73. https://doi.org/10.5281/zenodo.13941717.

Full text

Abstract:

Simple, rapid, cost-effective, sensitive spectrophotometric methods were developed for the determination of antivirus C drug (Daclatasvir dihydrochloride) in pure and dosage forms. The methods are based on the formation of ion-pair complexes between the drug and acid dyes (<em>i.e</em>., Bromothymol blue (BTB), bromocresol green (BCG) and bromophenol blue (BPB) solutions. The formed complexes were measured at 420, 416 and 415 nm for BCG, BPB and BTB methods, respectively, against a similarly prepared blank reagent. The analytical parameters and their effects on the reported systems were invest

APA, Harvard, Vancouver, ISO, and other styles

16

S. Eldin, Amira, Mona M. Abdel-Moety, Aliaa S. M. El-Tantawy, Abdalla Shalaby, and Magda El-Maamly. "Simple Potentiometric Strategy for the Detection of Levofloxacin Hydrochloride and Daclatasvir Dihydrochloride in Pure form and Pharmaceutical Preparations." Oriental Journal of Chemistry 34, no. 2 (2018): 913–21. http://dx.doi.org/10.13005/ojc/340240.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Naseef, Abanoub, Fatehy M. Abdel-Haleem, Magdy Kandil Zahran, and Ahmed Barhoum. "Acrylic molecularly imprinted polymer-based electrochemical sensor for precise nanomolar quantification of daclatasvir dihydrochloride in Daclavirdin®, Serum, and Urine." Microchemical Journal 208 (January 2025): 112389. https://doi.org/10.1016/j.microc.2024.112389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

El Azab, Noha F., Sally S. El-Mosallamy, Amr M. Mahmoud, and Yossra A. Trabik. "Design of a core-shell molecularly imprinted polymer for highly selective detection of daclatasvir dihydrochloride in tablets and human plasma." Microchemical Journal 213 (June 2025): 113723. https://doi.org/10.1016/j.microc.2025.113723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Abdel Ghani, Nour T., Hend Abdulla, Mahmoud S. Rizk, Ahmed S. Abo Dena, and Rasha Mohamed El Nashar. "Molecularly imprinted polymer/reduced graphene oxide‒based carbon‒paste sensor for highly sensitive determination of the anti‒HCV drug daclatasvir dihydrochloride." Sensors and Actuators B: Chemical 283 (March 2019): 6–17. http://dx.doi.org/10.1016/j.snb.2018.11.158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Badawy, Sayed S., Yomna M. Ahmed, Fatehy M. Abdel-Haleem, and Ahmed Barhoum. "Ionophore-Based Nanosphere Emulsion Incorporating Ion-Exchanger for Picogram Potentiometric Determination of HCV Drug (Daclatasvir) in Pharmaceutical Formulations and Body Fluids." Chemosensors 11, no. 7 (2023): 385. http://dx.doi.org/10.3390/chemosensors11070385.

Full text

Abstract:

Daclatasvir dihydrochloride (DAC) is a drug used to treat hepatitis C virus (HCV) infection. In this study, an ionophore-based nanosphere emulsion was made of tricresyl phosphate (TCP) as the oil phase that is dispersed in water using Pluronic F-127 as an emulsifying agent. The nanospheres, consisting of the oil phase TCP, were doped with sodium tetraphenyl borate (Na-TPB) as a cation-exchanger and dibenzo-18-Crown-6 (DB18C6) as an ionophore (chelating agent) for DAC. The nanosphere emulsion was employed as a titrant in the complexometric titration of DAC (the analyte), and the DAC-selective e

APA, Harvard, Vancouver, ISO, and other styles

21

Rathod, Sapna M., and Paresh U. Patel. "Development and Validation for Simultaneous Estimation of Sofosbuvir and Daclatasvir Dihydrochloride in Pharmaceutical Dosage form by Ratio Derivative and Dual Wavelength Methods." International Journal of Pharmaceutical Quality Assurance 11, no. 01 (2020): 25–31. http://dx.doi.org/10.25258/ijpqa.11.1.4.

Full text

Abstract:

Development and validation of new simple, sensitive, accurate and precise spectrophotometric method involving ratio derivative and dual-wavelength method, was done as per ICH Q2 (R1) for simultaneous estimation of Sofosbuvir (SOFO) and daclatasvir dihydrochloride (DACLA) in a combined dosage form. The overlapping in the spectra of both drugs was the reason for the selection of both methods. The absorbance difference (ΔA) value between 235.8 nm and 270.6 nm was selected for the quantitative determination of SOFO, where DACLA gives equal absorbance at the selected wavelength in the dual-waveleng

APA, Harvard, Vancouver, ISO, and other styles

22

Swain, Debasish, Amrej Singh Yadav, Venkatakrishna Akula, Srinivasu Pamidi, and Gananadhamu Samanthula. "Development of Stability Indicating Assay Method for Separation and Identification of Degradation Products of Daclatasvir Dihydrochloride by LC-ESI-QTOF-MS/MS." Analytical Chemistry Letters 9, no. 2 (2019): 209–22. http://dx.doi.org/10.1080/22297928.2019.1614090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Urvisha, Panchal, Parikh Nisha, Shah Ragin, and Patwari Arpit. "Novel Stability-Indicating High-Performance Thin Layer Chromatography (HPTLC) Method Development and Validation for Estimation of Daclatasvir Dihydrochloride in Pharmaceutical Dosage Form." Analytical Chemistry Letters 10, no. 3 (2020): 402–13. http://dx.doi.org/10.1080/22297928.2020.1779812.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ahmed, Yomna M., Sayed S. Badawy, and Fatehy M. Abdel-Haleem. "Dibenzo-18-crown-6-based carbon paste sensors for the nanomolar potentiometric determination of daclatasvir dihydrochloride: An anti-HCV drug and a potential candidate for treatment of SARS-CoV-2." Microchemical Journal 177 (June 2022): 107276. http://dx.doi.org/10.1016/j.microc.2022.107276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sayed, Rania A., Ahmed R. Mohamed, Wafaa S. Hassan, and Manal S. Elmasry. "Comparative study of four innovative earth-friendly platforms for rapid analysis of daclatasvir dihydrochloride: Application on different matrices." BMC Chemistry 17, no. 1 (2023). http://dx.doi.org/10.1186/s13065-023-00923-4.

Full text

Abstract:

Abstract Background Daclatasvir dihydrochloride has important roles not only in the management of COVID-19 pandemic symptoms but also in the treatment of chronic hepatitis C infection. Objective The current research presents four novel and simple platforms including silver-nanoparticles spectrophotometric technique and three electrochemical conductometric ones for daclatasvir analysis in its tablet, biological fluids, and dissolution media. Methods The spectrophotometric platform involved the synthesis of silvernanoparticles through a redox reaction between the reducing agent (daclatasvir) and

APA, Harvard, Vancouver, ISO, and other styles

26

El-Shorbagy, Hanan I., Mona A. Mohamed, Alaa El-Gindy, Ghada M. Hadad, and Fathalla Belal. "Development of UPLC method for simultaneous assay of some COVID-19 drugs utilizing novel instrumental standard addition and factorial design." Scientific Reports 13, no. 1 (2023). http://dx.doi.org/10.1038/s41598-023-32405-x.

Full text

Abstract:

AbstractA green, rapid, and simple RP-UPLC method was developed and optimized by full factorial design for the simultaneous separation of oseltamivir phosphate, daclatasivir dihydrochloride, and remdesivir, with dexamethasone as a co-administered drug. The separation was established on a UPLC column BEH C18 1.7 µm (2.1 × 100.0 mm) connected with a UPLC pre-column BEH 1.7 µm (2.1 × 5.0 mm) at 25 °C with an injection volume of 10 µL. The detector (PDA) was set at 239 nm. The mobile phase consisted of methanol and ammonium acetate (8.1818 mM) in a ratio of 75.7: 24.3 (v/v). The flow rate was set

APA, Harvard, Vancouver, ISO, and other styles

27

K, SUDHAMANI, and JEEVANA JYOTHI B. "DACLATASVIR DIHYDROCHLORIDE MICROSPHERES, PROCESS PARAMETERS FOR ENHANCED PERMEABILITY AND LIVER TARGETING." Asian Journal of Pharmaceutical and Clinical Research, December 7, 2022, 179–83. http://dx.doi.org/10.22159/ajpcr.2022.v15i12.46596.

Full text

Abstract:

Objectives: Daclatasavir dihydrochloride (DCLD) is used to treat hepatitis C. DCLD can be used to patients with all stages of compensated liver disease including cirrhosis. The aim of the present study was to develop DCLD microspheres to improve the permeation and maximum accumulation in the liver and in vitro evaluation. Methods: DCLD microspheres were prepared with chitosan polymer using emulsion crosslinking technique. Twelve formulations were prepared, that is, F1-F12. The microspheres were evaluated for morphology, particle size, encapsulation efficiency, % yield, and permeability. FTIR s

APA, Harvard, Vancouver, ISO, and other styles

28

Chaturvedi, Prashant, Shruti Chopra, Kalyani Joshi, and Savita Tauro. "Quality by Design-driven Analytical Method: A Quality Risk Management-Based Liquid Chromatography Method for Daclatasvir and Characterization of its Putative Degradants by LC-MS/MS." Current Pharmaceutical Analysis 20 (April 29, 2024). http://dx.doi.org/10.2174/0115734129285465240408044841.

Full text

Abstract:

Background:: Antiviral drugs can cure more than 95 percent of people with hepatitis C, but the inaccessibility of quality affordable medicines and the lack of their uninterrupted supply pose a major challenge. Impurities in drugs have a significant impact on their quality and are one of the substantial causes of drug recalls, ultimately leading to the unavailability of the drug in the market. Hence, there is a need for a robust, quality risk management and quality by design-driven analytical method that can detect the antiviral drug, Daclatasvir dihydrochloride, in the presence of its probable

APA, Harvard, Vancouver, ISO, and other styles

29

ABOUHUSSEIN, DALIA, MAHMOUD H. TEAIMA, ADI AL-NUSEIRAT, OSAMA BADARY, MOHAMED A. EL-NABARAWI, and REHAB ABD EL-MONEM. "FORMULATION AND CHARACTERIZATION OF ODT USING DIFFERENT CO-PROCESS CONTAINING DACLATSVIR: IN VITRO AND IN VIVO PHARMACOKINETICS STUDY ON HEALTHY VOLUNTEERS FOR HEPATITIS C TREATMENT." International Journal of Applied Pharmaceutics, September 7, 2022, 105–12. http://dx.doi.org/10.22159/ijap.2022v14i5.44289.

Full text

Abstract:

Objective: This study aimed to prepare and evaluate oral disintegrating tablets (ODTs) of Daclatasvir dihydrochloride (DCV) using different co-processed excipients to enhance drug dissolution and improve oral bioavailability for the treatment of hepatitis C infection. Methods: Ten Daclatasvir-ODTs formulae were prepared using co-processed excipients via direct compression. The prepared formulae were evaluated according to taste masking, weight variation, thickness, friability, hardness, drug content, and wetting time. In vitro disintegration time, in vivo disintegration time, and in vitro diss

APA, Harvard, Vancouver, ISO, and other styles

30

"SH229 Tablets Combined With Daclatasvir Dihydrochloride Tablets in Treatment Adult Patients With Chronic Hepatitis C." Case Medical Research, August 27, 2019. http://dx.doi.org/10.31525/ct1-nct04070235.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

EL-Shorbagy, Hanan I., Mona A. Mohamed, Alaa El-Gindy, Ghada M. Hadad, and Fathalla Belal. "UPLC-PDA factorial design assisted method for simultaneous determination of oseltamivir, dexamethasone, and remdesivir in human plasma." Scientific Reports 14, no. 1 (2024). http://dx.doi.org/10.1038/s41598-024-71413-3.

Full text

Abstract:

AbstractA green and simple UPLC method was developed and optimized, adopting a factorial design for simultaneous determination of oseltamivir phosphate and remdesivir with dexamethasone as a co-administered drug in human plasma and using daclatasvir dihydrochloride as an internal standard within 5 min. The separation was established on UPLC column BEH C18 1.7 μm (2.1 $$\times $$ × 100.0 mm) connected to UPLC pre-column BEH 1.7 μm (2.1 $$\times $$ × 5.0 mm) at 50 °C with an injection volume of 10 μL. The photodiode array detector (PDA) was set at three wavelengths of 220, 315, and 245 nm for os

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!